|
|
40
|
|
|
4181BJ
|
|
|
BEMABIX 25MG/ML INJ (ABB/PHA) BEVACIZUMAB
|
|
|
BEVACIZUMAB
|
|
|
BEMABIX
|
|
|
16ML VIAL
|
|
|
C
|
|
|
3,811.28
|
|
|
3,811.28
|
|
|
25MG/ML
|
|
|
INJECTION
|
|
|
0
|
|
|
VIAL
|
|
|
ABB
|
|
|
ABBOTT
|
|
|
PHA
|
|
|
PHARMACY SALES CARIBBEAN
|
|
|
|
|
|
Anti-Neoplastic
|
|
|
2022-04-01
|
|
|
2024-03-31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No
|
|
|
1000
|
|
|
ANTINEOPLASTICS
|
|
|
|
|
|
IV
|
|
|
0
|
|
|
ANTINEOPLASTICS
|
|
|
|